IPO News and Updates

7/25/14


Ocular Therapeutix, which develops eye therapies using a sustained-release hydrogel platform, raised $65 million by offering 5 million shares at $13, below the range of $14 to $16. Ocular Therapeutix plans to list on the NASDAQ under the symbol OCUL. Ocular Therapeutix initially filed confidentially on 4/29/2014. Morgan Stanley, Cowen & Company and RBC Capital Markets acted as lead managers on the deal.


Keywords: OCUL

7/24/14 Analyst IPO Blog


Two of the four IPOs on Thursday broke issue after pricing below the range. Less than a quarter of IPOs in the past three months have traded down on the first day. 

The top performer, Intersect ENT (XENT), priced at the low end and gained 18%. The company boasted impressive backers, high growth and more nasal implants in the pipeline. Immune Design (IMDZ), an early-stage biotech focused on immunotherapy to treat cancer, priced at the low end of the range and remained there by the end of the day.

Townsquare Media (TSQ), which operates 312 radio stations in mid-sized markets, priced 27% below the midpoint and ended the day down 7%. The company was brought out of bankruptcy by Oaktree Capital in a 2010 LBO. Radio stations, like newspapers, have struggled to maintain market share when competing with digital media. Pfenex (PFNX) was priced 54% below the midpoint and then fell 12%. It targets the lucrative wet AMD market, but the company is several years away from receiving FDA approval. 

Wednesday's microcap IPO Medical Transcription Billing (MTBC) also broke issue after pricing at half of the original range. It and Pfenex are among the year's highest-discounted offerings.

Thursday IPOs
Company (Ticker)                                Business                                                               Deal Size ($mm) IPO Price vs. Midpoint First Day Pop
Intersect ENT (XENT) Absorbable nasal implants $55 -8% 18%
Immune Design (IMDZ) Biotech: Immunotherapy for cancer $60 -8% 0%
Townsquare Media (TSQ) Oaktree-backed radio stations $92 -27% -7%
Pfenex (PFNX) Biotech: Wet AMD eye therapy $50 -54% -12%



Keywords: XENT, IMDZ, TSQ, PFNX

7/24/14


Advanced Drainage Systems, the world's largest provider of high density plastic pipe used in construction, raised $232 million by offering 14.5 million shares (64% insider) at $16, below the $17-$19 range. At its offer price and giving effect for 20.1 million shares that are convertible from its ESOP, Advanced Drainage now commands a $1.2 billion market cap and a $1.6 billion enterprise value. Advanced Drainage Systems will list on the NYSE under the symbol WMS. Barclays, Deutsche Bank, Citi and RBC Capital Markers acted as joint bookrunners on the deal.


Keywords: WMS

7/24/14


El Pollo Loco Holdings, a Tex-Mex fast food chain with 401 locations primarily in California, raised $107 million by offering 7.1 million shares at $15, the high end of the range of $13-$15. El Pollo Loco Holdings plans to list on the NASDAQ under the symbol LOCO. Jefferies & Co., Morgan Stanley and Baird were the bookrunners on the deal.


Keywords: LOCO

Archived News Headlines
Attribution Policy: The information contained herein is proprietary and copyrighted. The media is welcome to use our information and ideas, provided that the following sourcing is included: IPO investment firm Renaissance Capital (www.renaissancecapital.com).
Performance Disclosure: Past performance does not guarantee future results. The performance data quoted represents past performance and current returns may be lower or higher. The investment return and principal value of an investment will fluctuate so that an investor’s shares, when redeemed, may be worth more or less than the original cost. Investors should consider the investment objectives, risks, charges and expenses carefully before investing.

As stated in the Prospectus, the total annual operating expenses for the Fund was 3.48%. The Adviser has contractually agreed to keep net expenses from exceeding 2.50% of the Fund’s average daily net assets for at least a year from the date of the Prospectus and for an indefinite period thereafter subject to annual re-approval of the agreement by the Board of Trustees. An investor cannot invest directly in an index. Index returns do not represent Fund returns. The Index does not charge management fees or brokerage expenses, nor does the Index lend securities, and no revenues from securities lending were added to the performance shown.

Definitions: Net Asset Value (NAV) of the fund is calculated by dividing the total value of all the securities in its portfolio, less any liabilities, by the number of fund shares outstanding. Market Price is current value at which an asset or service can be bought or sold. Premium/Discount is provided to show the comparison of the daily net asset value (NAV) and the midpoint of the closing bid/ask for each of the funds. The Renaissance IPO Index® (IPOUSA) is a stock market index based upon a portfolio of U.S.-listed newly public companies that includes securities prior to their inclusion in core U.S. equity portfolios. The S&P 500® Index (SPX) is a stock market index based on the market capitalizations of 500 large companies whose common stock is publicly traded on the NYSE. The S&P 500 index components are determined by S&P Dow Jones Indices.

Risk Disclosure: Investments in the Renaissance IPO ETF, symbol "IPO" (the “ETF”) and the Global IPO Fund, symbol "IPOSX" (the “Mutual Fund”) are subject to investment risk, including possible loss of the principal amounts invested. The ETF and the Mutual Fund (the “Funds”) invest in companies that have recently completed their initial public offerings. These stocks are unseasoned equities lacking trading history, a track record of reporting to investors and widely available research coverage which many result in extreme price volatility. The Funds may also be subject to information technology risk and small and mid-capitalization company risk due to a greater number of IPOs in these sectors. The Funds may hold securities in the form of Depository Receipts, REITs, Master Limited Partnerships (MLPs) which have greater risks than common shares. The strategy has high portfolio turnover and securities lending risks. ETF returns may not match the return of the respective index. The ETF is classified as a non-diversified investment company and is subject to concentration risk.

Prospectus: Investors should consider the investment objectives, risks, charges and expenses carefully before investing. For a prospectus and/or summary prospectus with information about the Funds, please visit www.renaissancecapital.com. Read the prospectus carefully before investing. Renaissance Capital Investments, Inc., distributor for the Mutual Fund. Foreside Fund Services, LLC, distributor for the ETF, 1-866-486-6645.
Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital, the Renaissance IPO ETF (symbol: IPO) or the Global IPO Fund (symbol: IPOSX), may have investments in securities of companies mentioned.